114 related articles for article (PubMed ID: 38064536)
1. Radiolabelled
Cieslik PA; Klingler S; Nolff M; Holland JP
Chemistry; 2024 Mar; 30(14):e202303805. PubMed ID: 38064536
[TBL] [Abstract][Full Text] [Related]
2. Light-Induced Radiosynthesis of
Klingler S; Fay R; Holland JP
J Nucl Med; 2020 Jul; 61(7):1072-1078. PubMed ID: 31924725
[TBL] [Abstract][Full Text] [Related]
3. Dual-Receptor-Targeted Radioimmunotherapy of Human Breast Cancer Xenografts in Athymic Mice Coexpressing HER2 and EGFR Using 177Lu- or 111In-Labeled Bispecific Radioimmunoconjugates.
Razumienko EJ; Chen JC; Cai Z; Chan C; Reilly RM
J Nucl Med; 2016 Mar; 57(3):444-52. PubMed ID: 26429962
[TBL] [Abstract][Full Text] [Related]
4. Clinical Dose Preparation of [
Menon SR; Mitra A; Chakraborty A; Tawate M; Sahu S; Rakshit S; Gaikwad S; Dhotre G; Damle A; Banerjee S
Cancer Biother Radiopharm; 2022 Jun; 37(5):384-402. PubMed ID: 35575711
[No Abstract] [Full Text] [Related]
5. A comparison of DFO and DFO* conjugated to trastuzumab-DM1 for complexing
Cho H; Al-Saden N; Lam H; Möbus J; Reilly RM; Winnik MA
Nucl Med Biol; 2020; 84-85():11-19. PubMed ID: 31931305
[TBL] [Abstract][Full Text] [Related]
6. Preclinical characterisation of 111In-DTPA-trastuzumab.
Lub-de Hooge MN; Kosterink JG; Perik PJ; Nijnuis H; Tran L; Bart J; Suurmeijer AJ; de Jong S; Jager PL; de Vries EG
Br J Pharmacol; 2004 Sep; 143(1):99-106. PubMed ID: 15289297
[TBL] [Abstract][Full Text] [Related]
7. Panitumumab Modified with Metal-Chelating Polymers (MCP) Complexed to
Aghevlian S; Lu Y; Winnik MA; Hedley DW; Reilly RM
Mol Pharm; 2018 Mar; 15(3):1150-1159. PubMed ID: 29314858
[TBL] [Abstract][Full Text] [Related]
8. Evaluation of
Fiedler L; Kellner M; Gosewisch A; Oos R; Böning G; Lindner S; Albert N; Bartenstein P; Reulen HJ; Zeidler R; Gildehaus FJ
Nucl Med Biol; 2018 May; 60():55-62. PubMed ID: 29571067
[TBL] [Abstract][Full Text] [Related]
9. Bispidine Chelators for Radiopharmaceutical Applications with Lanthanide, Actinide, and Main Group Metal Ions.
Kopp I; Cieslik P; Anger K; Josephy T; Neupert L; Velmurugan G; Gast M; Wadepohl H; Brühlmann SA; Walther M; Kopka K; Bachmann M; Stephan H; Kubeil M; Comba P
Inorg Chem; 2023 Dec; 62(50):20754-20768. PubMed ID: 37707798
[TBL] [Abstract][Full Text] [Related]
10. Development of Lu-177-trastuzumab for radioimmunotherapy of HER2 expressing breast cancer and its feasibility assessment in breast cancer patients.
Bhusari P; Vatsa R; Singh G; Parmar M; Bal A; Dhawan DK; Mittal BR; Shukla J
Int J Cancer; 2017 Feb; 140(4):938-947. PubMed ID: 27813061
[TBL] [Abstract][Full Text] [Related]
11. [
Lau J; Kwon D; Rousseau E; Zhang Z; Zeisler J; Uribe CF; Kuo HT; Zhang C; Lin KS; Bénard F
Mol Pharm; 2019 Nov; 16(11):4688-4695. PubMed ID: 31545614
[TBL] [Abstract][Full Text] [Related]
12. Tracer level radiochemistry to clinical dose preparation of (177)Lu-labeled cyclic RGD peptide dimer.
Chakraborty S; Sarma HD; Vimalnath KV; Pillai MR
Nucl Med Biol; 2013 Oct; 40(7):946-54. PubMed ID: 23850487
[TBL] [Abstract][Full Text] [Related]
13. [
Kondo M; Cai Z; Chan C; Forkan N; Reilly RM
EJNMMI Radiopharm Chem; 2023 Sep; 8(1):24. PubMed ID: 37750937
[TBL] [Abstract][Full Text] [Related]
14. Pre-Clinical Assessment of Lu-Labeled Trastuzumab Targeting HER2 for Treatment and Management of Cancer Patients with Disseminated Intraperitoneal Disease.
Ray GL; Baidoo KE; Keller LM; Albert PS; Brechbiel MW; Milenic DE
Pharmaceuticals (Basel); 2011 Dec; 5(1):1-15. PubMed ID: 22229017
[TBL] [Abstract][Full Text] [Related]
15. Dose predictions for [
Ku A; Kondo M; Cai Z; Meens J; Li MR; Ailles L; Reilly RM
EJNMMI Radiopharm Chem; 2021 Aug; 6(1):25. PubMed ID: 34383182
[TBL] [Abstract][Full Text] [Related]
16. Measuring the pharmacodynamic effects of a novel Hsp90 inhibitor on HER2/neu expression in mice using Zr-DFO-trastuzumab.
Holland JP; Caldas-Lopes E; Divilov V; Longo VA; Taldone T; Zatorska D; Chiosis G; Lewis JS
PLoS One; 2010 Jan; 5(1):e8859. PubMed ID: 20111600
[TBL] [Abstract][Full Text] [Related]
17. Mechanisms of Cell Killing Response from Low Linear Energy Transfer (LET) Radiation Originating from (177)Lu Radioimmunotherapy Targeting Disseminated Intraperitoneal Tumor Xenografts.
Yong KJ; Milenic DE; Baidoo KE; Brechbiel MW
Int J Mol Sci; 2016 May; 17(5):. PubMed ID: 27196891
[TBL] [Abstract][Full Text] [Related]
18. Anti-L1CAM radioimmunotherapy is more effective with the radiolanthanide terbium-161 compared to lutetium-177 in an ovarian cancer model.
Grünberg J; Lindenblatt D; Dorrer H; Cohrs S; Zhernosekov K; Köster U; Türler A; Fischer E; Schibli R
Eur J Nucl Med Mol Imaging; 2014 Oct; 41(10):1907-15. PubMed ID: 24859811
[TBL] [Abstract][Full Text] [Related]
19. Assessment of PSMA targeting ligands bearing novel chelates with application to theranostics: Stability and complexation kinetics of
Kelly JM; Amor-Coarasa A; Nikolopoulou A; Kim D; Williams C; Vallabhajosula S; Babich JW
Nucl Med Biol; 2017 Dec; 55():38-46. PubMed ID: 29055836
[TBL] [Abstract][Full Text] [Related]
20. Effects of adding an albumin binder chain on [
Rousseau E; Lau J; Zhang Z; Uribe CF; Kuo HT; Zhang C; Zeisler J; Colpo N; Lin KS; Bénard F
Nucl Med Biol; 2018 Nov; 66():10-17. PubMed ID: 30170196
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
